Report copyright - NOVEMBER 2016 - MorphoSys...Preliminary data of an ongoing Phase 1/2a study of MOR202 in patients with rrMM demonstrate best-in-class infusion tolerability, favorable safety and encouraging
Please pass captcha verification before submit form